

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all previous versions and listings of the claims in the application.

1 – 16. (canceled)

17. (currently amended) ~~The fusion molecule of claim 4~~ An isolated fusion molecule comprising a first polypeptide sequence comprising a native human IgG heavy chain constant region capable of specific binding to a native IgG inhibitory receptor, wherein said IgG heavy chain constant region sequence is the sequence of SEQ ID NO: 2, directly functionally connected to a second polypeptide autoantigen sequence comprising at least 90% sequence identity to a portion of the amino acid sequence of myelin basic protein (MBP) and capable of specific binding to an IgE class immunoglobulin specific for MBP.

18 – 20. (canceled)

21. (currently amended) ~~The fusion molecule of claim 20~~ An isolated fusion molecule comprising a first polypeptide sequence comprising a native human IgG heavy chain constant region capable of specific binding to a native IgG inhibitory receptor, wherein said first polypeptide sequence comprises an amino acid sequence having at least 98% identity to the amino acid sequence of SEQ ID NO: 3, directly functionally connected to a second polypeptide autoantigen sequence comprising at least 90% sequence identity to a portion of the amino acid sequence of myelin basic protein (MBP) and capable of specific binding to an IgE class immunoglobulin specific for MBP.

22. (original) The fusion molecule of claim 21 wherein said first polypeptide sequence comprises at least part of the CH2 and CH3 domains of a native human IgG₁ constant region.

23. (original) The fusion molecule of claim 22 wherein said first polypeptide sequence additionally comprises at least part of the hinge of a native human IgG₁ constant region.
24. (previously presented) The fusion molecule of claim 23 wherein said first polypeptide sequence comprises at least part of the hinge, CH2 and CH3 domains of a native human IgG₁ heavy chain constant region, in the absence of a functional CH1 region.
25. (canceled)
26. (currently amended) The fusion molecule of claim 4 17 wherein said first polypeptide sequence and said second polypeptide autoantigen sequence are functionally connected through a linker.
27. (original) The fusion molecule of claim 26 wherein said linker is a polypeptide linker.
28. (previously presented) The fusion molecule of claim 27 wherein said polypeptide linker sequence consists of about 5 to about 25 amino acid residues.
29. (currently amended) The fusion molecule of claim 4 17, wherein said fusion molecule comprises at least one amino terminal ubiquitination target motif.
30. (currently amended) The fusion molecule of claim 4 17, wherein said fusion molecule comprises at least one proteasome proteolysis signal, wherein said signal is selected from the group consisting of large hydrophobic amino acid residues, basic amino acid residues and acidic amino acid residues.
31. (previously presented) The fusion molecule of claim 27, wherein said polypeptide linker comprises at least one proteasome proteolysis signal, wherein said signal is

selected from the group consisting of large hydrophobic amino acid residues, basic amino acid residues and acidic amino acid residues.

32. (previously presented) The fusion molecule of claim 27 wherein said polypeptide linker sequence comprises at least one endopeptidase recognition motif.

33. (previously presented) The fusion molecule of claim 27 wherein said polypeptide linker sequence comprises a plurality of endopeptidase recognition motifs.

34. (previously presented) The fusion molecule of claim 32 wherein said endopeptidase recognition motif is selected from the group consisting of cysteine, aspartate and asparagine amino acid residues.

35 – 39. (canceled)

40. (currently amended) A pharmaceutical composition comprising a fusion molecule of claim 4 17 in admixture with a pharmaceutically acceptable excipient.

41. (currently amended) A pharmaceutical composition comprising a fusion molecule of claim 9 21 in admixture with a pharmaceutically acceptable ingredient.

42. (currently amended) An article of manufacture comprising a container, a fusion molecule of claim 4 17 within the container, and a label or package insert on or associated with the container.

43. (currently amended) An article of manufacture comprising a container, a fusion molecule of claim 9 21 within the container, and a label or package insert on or associated with the container.

44. (original) The article of manufacture of claim 42 wherein said label or package insert comprises instructions for the treatment or prevention of an immune disease.

45 – 59. (canceled)

60. (new) The fusion molecule of claim 21 wherein said first polypeptide sequence and said second polypeptide autoantigen sequence are functionally connected through a linker.

61. (new) The fusion molecule of claim 60 wherein said linker is a polypeptide linker.

62. (new) The fusion molecule of claim 61 wherein said polypeptide linker sequence consists of about 5 to about 25 amino acid residues.

63. (new) The fusion molecule of claim 21, wherein said fusion molecule comprises at least one amino terminal ubiquitination target motif.

64. (new) The fusion molecule of claim 21, wherein said fusion molecule comprises at least one proteasome proteolysis signal, wherein said signal is selected from the group consisting of large hydrophobic amino acid residues, basic amino acid residues and acidic amino acid residues.

65. (new) The fusion molecule of claim 61, wherein said polypeptide linker comprises at least one proteasome proteolysis signal, wherein said signal is selected from the group consisting of large hydrophobic amino acid residues, basic amino acid residues and acidic amino acid residues.

66. (new) The fusion molecule of claim 61 wherein said polypeptide linker sequence comprises at least one endopeptidase recognition motif.

67. (new) The fusion molecule of claim 61 wherein said polypeptide linker sequence comprises a plurality of endopeptidase recognition motifs.

68. (new) The fusion molecule of claim 66 wherein said endopeptidase recognition motif is selected from the group consisting of cysteine, aspartate and asparagine amino acid residues.